Scholars Central

Research articlePublished 19 Apr 2014

XB130 Expression in Human Osteosarcoma: A Clinical and Experimental Study

Authors: Xiaohui Wang, Hai Huang, Fengyun Hao, Yu Li, Lin Zhang

1Department of Orthopedics, The central hospital of Yishui, China; 2Department of Orthopedics, the Linyi People’s Hospital, China; 3Department of Pathology, Affiliated Hospital of medical college, Qingdao University, China; 4Department of Anesthesiology, Affiliated Hospital of medical college, Qingdao University, China

Journal of Clinical & Experimental Pathology

Volume 4 · Issue 3 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Identifying prognostic factors for osteosarcoma (OS) aids in the selection of patients who require more aggressive management. XB130 is a newly characterized adaptor protein that was reported to be to be a prognostic factor of certain tumor types. However, the association between XB130 expression and the prognosis of OS remains unknown. In the present study, we investigated the association between XB130 expression and clinicopathologic features and prognosis in patients suffering osteosarcoma, and further investigated its potential role on OS cells in vitro and vivo. A retrospective immunohistochemical study of XB130 was performed on archival formalin-fixed paraffin-embedded specimens from 60 pairs of osteosarcoma and noncancerous bone tissues, and compared the expression of XB130 with clinicopathological parameters. We then investigate the effect of XB130 silencing on invasion in vitro and lung metastasis in vivo of the human osteosarcoma cell line. Immunohistochemical assays revealed that XB130 expression in osteosarcoma tissues was significantly higher than that in corresponding noncancerous bone tissues (P=0.001). In addition, high XB130 expression more frequently occurred in osteosarcoma tissues with advanced clinical stage (P=0.002) and positive distant metastasis (P=0.001). Moreover, osteosarcoma patients with high XB130 expression had significantly shorter overall survival and disease-free survival (both P<0.001) when compared with patients with the low expression of XB130. The univariate analysis and multivariate analysis shown that high XB130 expression and distant metastasis were the independent poor prognostic factor. We showed that XB130 depletion by RNA interference inhibited invasion of XB130-rich U2OS cells in vitro and lung metastasis in vivo. This is the first study to reveal that XB130 overexpression may be related to the prediction of metastasis potency and poor prognosis for osteosarcoma patients, suggesting that XB130 may serve as a prognostic marker for the optimization of clinical treatments. Furthermore, XB130 is the potential molecular target for osteosarcoma therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Clinical & Experimental Pathology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pathology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Xiaohui Wang”
  • BylineArticles whose byline prints “Hai Huang”
  • BylineArticles whose byline prints “Fengyun Hao”
  • BylineArticles whose byline prints “Yu Li”
  • BylineArticles whose byline prints “Lin Zhang”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels